News and views from the world of clinical oncology and hematology
Huntington, NY
- Tweets 35,393
- Following 4,482
- Followers 62,542
- Likes 929
This week’s #ASCOAI Weekly News Brief covers:
🫁 A decision support tool sharpened physician predictions of immunotherapy outcomes in advanced #NSCLC
🩸A blood-based cfDNA fragmentome classifier detected more #livercancer than AFP
🎥 Watch here: ascoai.org/videos/weekly-bri…
3
2
590
🩸Excess toxicity and mortality prompted early closure of the double-hit #lymphoma cohort of ALLIANCE A051701.
Adding venetoclax to DA-EPOCH-R did not improve PFS in newly diagnosed disease.
▪️Jeremy Abramson, MD, MMSc | @TheLancetHaem
🔗 ascopost.com/news/september-…
1
3
4
854
🧬 CAP (@Pathologists) has updated 14 Cancer Protocols to reflect advances in #precisiononcology and evolving @WHO classifications, including changes to #BreastCancer biomarker reporting and molecular testing for GIST.
Learn more about the updates ➡️ ascopost.com/news/september-…
1
3
5
812
🖥️ #ASCOAI: The question isn’t whether #AI will replace physicians, it’s how AI can strengthen care
@jamecancerdoc of @ClevelandClinic explains why technology should protect time for trust, empathy, and the physician-patient relationship.
Learn more ➡️ ascoai.org/articles/2026/09/…
1
3
7
2,582
🫁 Updated PRESERVE-003 results support continued phase III evaluation of gotistobart in metastatic squamous #NSCLC after PD-(L)1 therapy, with improved OS vs docetaxel and no new safety signals.
🗣️ Presented by Rama Balaraman, MD at #WCLC26
🔗 ascopost.com/news/september-…
4
13
1,605
🚨 #FDAApproval: The @FDA has granted approval for belzutifan (Welireg) + lenvatinib (Lenvima) for adults with advanced clear cell #RCC following treatment with a PD-1/PD-L1 inhibitor.
Approval supported by LITESPARK-011 findings.
🔗 ascopost.com/news/september-…
2
2
1,063
📰 A new issue of The ASCO Post is LIVE.
Top stories include:
🔹 Changing clinician roles in the #AI era
🔹 Interview with E. Anders Kolb, MD, of @BloodCancerUtd
🔹 Perspective on next-generation KRAS G12C inhibitors in #NSCLC
Explore the full issue: ascopost.com/issues/septembe…
4
7
1,498
🫀Atrial fibrillation may add complexity to #CLL care.
@Dr_Mike_Fradley MD, discusses #ASCO26 research evaluating cardiovascular outcomes and health-care utilization among patients with CLL, including analyses by age and treatment.
🎥 Watch here: ascopost.com/videos/asco-202…
4
5
1,364
🖥️ #ASCOAI: In I³LUNG, an #AI decision support tool using clinical & blood data outperformed standard biomarkers for predicting immunotherapy outcomes in advanced #NSCLC.
🔹 Led by Arsela Prelaj, MD @PrelajArsela & Marina Garassino, MD @marinagarassino
🔗 ascoai.org/articles/2026/09/…
6
6
1,767
✅ An @FDA advisory committee voted 7–2 that the benefits of the Galleri multi-cancer early detection test outweigh its risks, with 1 abstention.
The FDA will consider the recommendation for the pre-market approval application.
Learn more 👉 ascopost.com/news/september-…
1
3
3
1,418
🧬Anbenitamab + HB1801 chemotherapy improved pathologic complete response across key subgroups of ERBB2-positive #BreastCancer in phase III Neo-Healer, including HR+ and HR− disease, with or without carboplatin.
▪️Drs. Zhi-Ming Shao & Lei Fan | @JAMAOnc
🔗ascopost.com/news/september-…
1
6
19
2,123
🫁 Not all BRAF alterations behave the same in #NSCLC.
🆕 data show class 2️⃣ and 3️⃣ mutations have distinct clinicopathologic features, co-mutation patterns, and outcomes, with class 3️⃣ linked to worse OS.
🗣️ Presented by @DiFedericoMD at #WCLC26
🔗 ascopost.com/news/september-…
2
7
12
2,030
🚨 #FDAApproval: The @FDA has granted approval for lirafugratinib (Lyrfigtu), an FGFR2 inhibitor, for previously treated adults with unresectable locally advanced or metastatic FGFR2-altered #Cholangiocarcinoma.
Approval based on REFOCUS trial findings.
ascopost.com/news/fda-approv…
1
3
9
1,978
🫁 #ASCOAI: An explainable #AI model predicted grade ≥ 3 toxicity during neoadjuvant chemoimmunotherapy for patients with resectable #NSCLC, achieving an AUC of 0.800 internally and 0.728 in external validation. #WCLC26
Read more ➡️ ascoai.org/articles/2026/09/…
4
4
1,311
📃 The @AACR Cancer Progress Report 2026 highlights major gains against cancer:
🔹The U.S. #cancer death rate fell 35% from 1991–2024 = 4.8 million fewer deaths
🔹Overall 5-year survival rates for distant-stage disease have more than doubled
Learn more 👉 ascopost.com/news/september-…
1
5
810
🥬Could diet influence #ProstateCancer progression during active surveillance?
Greater adherence to a plant-based diet was associated with a 42% lower risk of disease upgrading in a prospective cohort
🔹Drs. Zhuo Tony Su & Christian P. Pavlovich | #AUA26
ascopost.com/news/september-…
6
11
2,035
🚺 Five-year KEYNOTE-826 data show sustained OS benefit with first-line pembrolizumab + chemotherapy in advanced #CervicalCancer.
In the PD-L1 CPS ≥1 group, mOS was 28.6 vs 16.5 months with placebo (HR = 0.62).
▪️Kosei Hasegawa, MD, PhD | @JAMAOnc
🔗 ascopost.com/news/september-…
1
6
16
2,033
💻 #ASCOAI: How can researchers use #AI without letting it limit innovation?
Brian Uzzi, PhD (@UzziLeadership) explains why AI may raise the floor of human ability while lowering the ceiling, and how to structure AI use to support more divergent thinking.
ascoai.org/articles/2026/09/…
2
6
1,041
👤 In phase 3️⃣ data, TMC-I reduced the risk of death by 43% vs paclitaxel/carboplatin in recurrent/metastatic #headandneckcancer.
➡️ Median OS was 10.3 vs 6.2 months
🗣️ Presented by Minit Jalan Shah, MBBS, MD, DM at #ASCO26
🔗 ascopost.com/news/september-…
5
17
2,115
💉GLP-1 RA use was associated with lower #BreastCancer detection in a large observational imaging study, including after propensity matching.
🥼Researchers caution the findings do not establish causality and call for prospective trials.
Learn more ➡️ ascopost.com/news/september-…
3
8
1,391